- Home
- BTAI vs APTO Comparison
BTAI vs APTO Comparison
Compare BTAI & APTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTAI
- APTO
- Stock Information
- Founded
- BTAI 2017
- APTO 1986
- Country
- BTAI United States
- APTO Canada
- Employees
- BTAI N/A
- APTO N/A
- Industry
- BTAI Biotechnology: Pharmaceutical Preparations
- APTO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BTAI Health Care
- APTO Health Care
- Exchange
- BTAI Nasdaq
- APTO Nasdaq
- Market Cap
- BTAI 7.2M
- APTO 6.8M
- IPO Year
- BTAI 2018
- APTO N/A
- Fundamental
- Price
- BTAI $1.88
- APTO $1.81
- Analyst Decision
- BTAI Buy
- APTO Strong Buy
- Analyst Count
- BTAI 5
- APTO 3
- Target Price
- BTAI $42.60
- APTO $112.00
- AVG Volume (30 Days)
- BTAI 1.2M
- APTO 53.6K
- Earning Date
- BTAI 03-27-2025
- APTO 05-13-2025
- Dividend Yield
- BTAI N/A
- APTO N/A
- EPS Growth
- BTAI N/A
- APTO N/A
- EPS
- BTAI N/A
- APTO N/A
- Revenue
- BTAI $2,266,000.00
- APTO N/A
- Revenue This Year
- BTAI $105.36
- APTO N/A
- Revenue Next Year
- BTAI $46.93
- APTO N/A
- P/E Ratio
- BTAI N/A
- APTO N/A
- Revenue Growth
- BTAI 64.20
- APTO N/A
- 52 Week Low
- BTAI $1.72
- APTO $1.35
- 52 Week High
- BTAI $49.58
- APTO $50.10
- Technical
- Relative Strength Index (RSI)
- BTAI 39.27
- APTO 40.05
- Support Level
- BTAI $1.76
- APTO $3.20
- Resistance Level
- BTAI $2.37
- APTO $3.76
- Average True Range (ATR)
- BTAI 0.28
- APTO 0.32
- MACD
- BTAI 0.03
- APTO 0.05
- Stochastic Oscillator
- BTAI 16.95
- APTO 14.79
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
About APTO Aptose Biosciences Inc.
Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities.